<DOC>
	<DOCNO>NCT02173210</DOCNO>
	<brief_summary>This project examine genetic metabolic marker use 17 hydroxyprogesterone caproate ( 17OHPC ) pregnant woman history preterm birth ( PTB ) . 17OHPC associated 30-35 % reduction repeat PTB woman carry singleton gestation . However , well know work woman others . There limited available intervention prevention recurrent PTB . This study enroll 150 woman risk PTB eligible receive 17OHPC , expect 80 % use 17OHPC 20 % decline use . We obtain blood sample sample cervical cell cervical vaginal fluid . The objective study identify genetic , microbial molecular marker help identify woman risk recurrent preterm birth respond 17OHPC woman . The ultimate goal develop personalized screen test base marker .</brief_summary>
	<brief_title>Precision Medicine Preterm Birth</brief_title>
	<detailed_description>Women prior preterm birth recruit 16 22 week gestation . At initial time point , sample cervical epithelial cell cervicovaginal fluid collect . Approximately 8 week later , sample collect second time , along blood sample . Outcome data collect delivery .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
	<mesh_term>11-hydroxyprogesterone</mesh_term>
	<criteria>Women prior spontaneous preterm birth singleton pregnancy ( delivered 1636 6/7 week gestation ) Singleton current pregnancy Eligible use 17 hydroxyprogesterone caproate ( 17OHPC ) pregnancy clinical indication 1622 week gestation time visit 1 assessment Major fetal anomaly Allergy 17OHPC</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Premature birth</keyword>
	<keyword>Premature delivery</keyword>
	<keyword>Metabolomics</keyword>
	<keyword>Microbiota</keyword>
	<keyword>Genetics</keyword>
	<keyword>17 hydroxyprogesterone caproate</keyword>
</DOC>